Sunshine Biopharma, Inc. (SBFM) Stock Analysis & Investment Frameworks

Sunshine Biopharma, Inc. (SBFM) stock analysis on Invetso. Review Sunshine Biopharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Sunshine Biopharma, Inc. Company Overview

Sunshine Biopharma, Inc. Key Financial Metrics

About Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.

Sunshine Biopharma, Inc. Investment Frameworks

Invetso analyzes Sunshine Biopharma, Inc. (SBFM) across the following frameworks:

Explore More SBFM Research

Invetso is not affiliated with or regulated by the U.S. Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA), or any other financial regulatory authority. The analyses, scores and all the information provided by Invetso are strictly for informational purposes only and do not constitute financial advice, recommendations, or an offer to buy or sell any securities. Invetso is not a registered financial advisor, broker-dealer, or investment advisor, and it does not provide personalized investment, legal, or tax advice. The content provided on this website is not intended to serve as a substitute for professional advice. Users should conduct their own research and consult with a qualified financial advisor before making any investment decisions. All analysis, data, and information presented on this site are based on publicly available information and should be used at the user’s own risk. Invetso does not guarantee the accuracy, completeness, or timeliness of any information or data provided, nor does it endorse any specific securities, companies, or strategies. Any reliance you place on such information is strictly at your own risk. While we strive to provide accurate and up-to-date information, Invetso makes no warranties or representations regarding the completeness, accuracy, or reliability of any analyses or data on our platform, and any such information is subject to the terms and conditions of the Invetso Terms of Service. Our analyses are generated using AI technologies and AI-generated content may contain errors or inaccuracies. Use the information at your own risk. Our platform may contain links to third-party websites, for which we are not responsible for the content or accuracy of information. Invetso shall not be liable for any loss or damage arising from the use of our services. By using this website, you agree that Invetso is not responsible for any losses, damages, or financial outcomes that may result from your use of the information, tools, or resources provided. We recommend consulting with a licensed financial professional before making any investment decisions.

For more details, please refer to our Terms of Service and Privacy Policy.